Compare BW & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BW | AMPH |
|---|---|---|
| Founded | 1867 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2015 | 2005 |
| Metric | BW | AMPH |
|---|---|---|
| Price | $3.59 | $28.39 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 7 |
| Target Price | $16.25 | ★ $24.50 |
| AVG Volume (30 Days) | ★ 5.1M | 433.1K |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.46 | N/A |
| EPS | N/A | ★ 1.67 |
| Revenue | ★ $1,062,388,000.00 | $719,887,000.00 |
| Revenue This Year | $86.64 | $3.81 |
| Revenue Next Year | $22.38 | $4.91 |
| P/E Ratio | ★ N/A | $16.84 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.07 | $16.65 |
| 52 Week High | $22.03 | $31.00 |
| Indicator | BW | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 35.91 | 54.84 |
| Support Level | $3.07 | $24.37 |
| Resistance Level | $4.68 | $29.23 |
| Average True Range (ATR) | 0.51 | 1.26 |
| MACD | 0.05 | -0.08 |
| Stochastic Oscillator | 21.57 | 36.22 |
Babcock & Wilcox Enterprises Inc is an energy technologies provider offering energy and emissions control solutions to a broad range of industrial, electrical utility, municipal, and other customers. It offers technologies that utilize coal, natural gas, hydrogen, waste, and biomass to produce energy, environmental solutions, and carbon capture systems. The company's product portfolio comprises steam generation systems, environmental solutions, combustion and fuel systems, and related equipment and services. Additionally, it offers specialized technologies (BrightLoop) in industrial energy production, including hydrogen and syngas. Geographically, the company generates maximum revenue from the United States, and the rest from Canada, the UK, Indonesia, the Philippines, and other markets.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.